Oncology PracticeFDA Expands Indication for Amivantamab in Lung CancerSeptember 23, 2024Lung CancerPractice Management
Oncology PracticeCancer Risk: Are Pesticides the New Smoking?September 20, 2024Preventive CareGastrointestinal CancerGastroenterologyPatient & Survivor CareBreast CancerCNS/Brain CancerFollicular Lymphoma
Oncology PracticeFDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer IndicationsSeptember 17, 2024Mixed TopicsMelanomaLung CancerSarcoma & GISTPatient & Survivor CarePractice Management
Oncology PracticeOsimertinib/Savolitinib Combo Shows Promise in NSCLCSeptember 17, 2024Lung CancerPatient & Survivor Care
Oncology PracticeIvonescimab: Possible New First-Line Standard in PD-L1–Positive Advanced NSCLC?September 9, 2024Lung CancerPatient & Survivor Care
Oncology PracticeDo Clonal Hematopoiesis and Mosaic Chromosomal Alterations Increase Solid Tumor Risk?September 6, 2024Breast CancerPatient & Survivor CarePreventive CareLung CancerGastroenterologyGastrointestinal CancerAggressive Lymphomas
Oncology PracticeSBRT vs Surgery in CRC Lung Metastases: Which Is Better?August 30, 2024Patient & Survivor CareGastroenterologyGastrointestinal CancerLung CancerMixed Topics
Oncology PracticeCancer Cases, Deaths in Men Predicted to Surge by 2050August 30, 2024Patient & Survivor CarePractice ManagementSarcoma & GISTRenal Cell CarcinomaNonmelanoma Skin CancerNeuro-oncologyMixed Topics
Oncology PracticeCancer Treatment 101: A Primer for Non-OncologistsAugust 23, 2024Breast CancerCNS/Brain CancerDLBCLFollicular LymphomaGastroenterologyGastrointestinal CancerImmunotherapy
Oncology PracticeFDA OKs First-Line Lazertinib With Amivantamab for NSCLCAugust 22, 2024Lung CancerPractice Management
Oncology PracticeWhen Childhood Cancer Survivors Face Sexual ChallengesAugust 22, 2024Mixed TopicsPediatricsPatient & Survivor CareALLCMLCLLGastroenterology
Oncology PracticeFew Severe Toxicities After SBRT in Oligometastatic CancerAugust 20, 2024Breast CancerLung CancerGastrointestinal CancerGenitourinary CancerImmunotherapy
Oncology PracticeFDA Approves Neoadjuvant/Adjuvant Durvalumab for NSCLCAugust 16, 2024Lung CancerPractice Management
Oncology PracticeImmunotherapy and Survival in Advanced NSCLC: Does Obesity Matter?August 12, 2024Lung CancerPatient & Survivor CareImmunotherapyImmuno-oncology
